Biosenic SA

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds

08 Jan 2024 09:00:00 By Nasdaq GlobeNewswire

ERRATUM: BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

07 Dec 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

05 Dec 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic provides third quarter 2023 Business Update

24 Oct 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024

17 Oct 2023 22:00:00 By Nasdaq GlobeNewswire

Correction: BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS

16 Oct 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD

26 Sep 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis

18 Sep 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts

13 Sep 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic reports half year 2023 results

06 Sep 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

31 Aug 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases

23 Aug 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

02 Aug 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic provides further update on negotiations with its main creditors

09 Jul 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

02 Jul 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic provides financial update

29 Jun 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic presents data on its new copper-arsenic trioxide combination for immunological disorders at the 25th International Conference on Redox Medicine

20 Jun 2023 02:31:14 By Nasdaq GlobeNewswire

BioSenic puts Phase IIb ALLOB trial on hold

18 Jun 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic SA : Information on the total number of voting rights and shares

31 May 2023 22:00:00 By Nasdaq GlobeNewswire

BioSenic provides update regarding current license agreement with Phebra

28 May 2023 22:00:00 By Nasdaq GlobeNewswire